These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

807 related articles for article (PubMed ID: 17207959)

  • 1. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma.
    Papadakou M; Xydakis E; Bonios M; Makropoulou E; Boukis C; Kakavoulis T; Karaliotas C; Panagos G
    J BUON; 2006; 11(3):285-9. PubMed ID: 17309151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
    Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
    Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Adjuvant chemotherapy in gastric cancer. Experience at the National Institute of Nutrition].
    León Rodríguez E; Domínguez A
    Rev Invest Clin; 1992; 44(2):221-7. PubMed ID: 1439310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
    Di Costanzo F; Gasperoni S; Manzione L; Bisagni G; Labianca R; Bravi S; Cortesi E; Carlini P; Bracci R; Tomao S; Messerini L; Arcangeli A; Torri V; Bilancia D; Floriani I; Tonato M; ; Dinota A; Strafiuso G; Corgna E; Porrozzi S; Boni C; Rondini E; Giunta A; Monzio Compagnoni B; Biagioni F; Cesari M; Fornarini G; Nelli F; Carboni M; Cognetti F; Enzo MR; Piga A; Romiti A; Olivetti A; Masoni L; De Stefanis M; Dalla Mola A; Camera S; Recchia F; De Filippis S; Scipioni L; Zironi S; Luppi G; Italia M; Banducci S; Pisani Leretti A; Massidda B; Ionta MT; Nicolosi A; Canaletti R; Biscottini B; Grigniani F; Di Costanzo F; Rovei R; Croce E; Carroccio R; Gilli G; Cavalli C; Olgiati A; Pandolfi U; Rossetti R; Natalini G; Foa P; Oldani S; Bruno L; Cascinu S; Catalano G; Catalano V; Lungarotti F; Farris A; Sarobba MG; Trignano M; Muscogiuri A; Francavilla F; Figoli F; Leoni M; Papiani G; Orselli G; Antimi M; Bellini V; Cabassi A; Contu A; Pazzola A; Frignano M; Lastraioli E; Saggese M; Bianchini D; Antonuzzo L; Mela M; Camisa R
    J Natl Cancer Inst; 2008 Mar; 100(6):388-98. PubMed ID: 18334706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
    Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
    J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
    Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
    Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer.
    Grau JJ; Martín M; Fuster J; Pera M; García-Valdecasas JC; Bombí JA; Bordas JM; Alcobendas F; Grande L; Estapé J
    J Surg Oncol; 2003 Apr; 82(4):234-40. PubMed ID: 12672007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric carcinoma: curative resection and adjuvant chemotherapy.
    Carrillo Hernández JF; Ernesto de Obaldía Castillo G; Ramírez Ortega C; Frías Mendivil M; Pardo M
    Arch Med Res; 1994; 25(1):29-35. PubMed ID: 8019111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
    Kim S; Lim DH; Lee J; Kang WK; MacDonald JS; Park CH; Park SH; Lee SH; Kim K; Park JO; Kim WS; Jung CW; Park YS; Im YH; Sohn TS; Noh JH; Heo JS; Kim YI; Park CK; Park K
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1279-85. PubMed ID: 16099596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of immunochemo-surgery for gastric carcinoma.
    Kim JP; Yu HJ; Lee JH
    Hepatogastroenterology; 2001; 48(41):1227-30. PubMed ID: 11677936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
    Cho BC; Jeung HC; Choi HJ; Rha SY; Hyung WJ; Cheong JH; Noh SH; Chung HC
    J Surg Oncol; 2007 May; 95(6):461-8. PubMed ID: 17192913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 protein expression in gastric adenocarcinoma. Negative predictor of survival after postoperative adjuvant chemotherapy.
    Díez M; Medrano MJ; Gutierrez A; López A; Mugüerza JM; Hernández P; Lozano O; Noguerales F; Ruíz A; Granell J
    Anticancer Res; 2000; 20(5C):3929-33. PubMed ID: 11268479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
    Chen S; Chen YB; Zhou ZW; Li W; Sun XW; Xu DZ; Li YF; Guan YX; Feng XY; Zhan YQ
    Am J Clin Oncol; 2011 Jun; 34(3):309-13. PubMed ID: 20838324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
    De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
    Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
    Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
    Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-operative chemotherapy in non-curative gastrectomy for advanced gastric cancer.
    Hanazaki K; Mochizuki Y; Machida T; Yokoyama S; Sodeyama H; Sode Y; Wakabayashi M; Kawamura N; Miyazaki T
    Hepatogastroenterology; 1999; 46(26):1238-43. PubMed ID: 10370699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer.
    Chipponi J; Huguier M; Pezet D; Basso N; Hay JM; Quandalle P; Jaeck D; Fagniez PL; Gainant A
    Am J Surg; 2004 Mar; 187(3):440-5. PubMed ID: 15006580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.